Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1-positive acute lymphoblastic leukemia.
- Resource Type
- Academic Journal
- Authors
- Walczak P; Hôpital Saint-Louis, APHP, Paris, France.; Fodil S; Hopital Saint-Louis, Paris, France.; Vignal N; Saint-Louis Hospital, France.; Cabannes-Hamy A; Université de Paris Cité, France.; Boissel N; Hopital Saint-Louis, AP-HP, Paris, France.; Raffoux E; Hopital Saint Louis, PARIS, France.; Cayuela JM; Centre hospitalier de Versailles, France.; Goldwirt L; APHP, Hôpital Saint-Louis, Paris, France.; Lengliné E; Saint Louis hospital, Paris, France.
- Source
- Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
- Subject
- Language
- English
Tyrosine kinase inhibitors have improved outcomes in Philadelphia-positive ALL, but their efficacy in CNS disease remains uncertain. Ponatinib was studied for CNS distribution in 22 samples from 16 patients. CSF concentrations fell below the 40nM threshold, suggesting suboptimal CNS exposure.
(Copyright © 2024 American Society of Hematology.)